Abstract: Disclosed herein is a bioenergy production system with reduced carbon dioxide emissions and process wastes; including a process for producing a bioalcohol and a biogas by subjecting a biomass, such as: herbaceous and woody plants, fruit pulp, freshwater and sea algae, grains, aerobic and anaerobic sludge, saccharides, polyols and carbohydrates, to a combined process of a biosaccharification/alcohol fermentation, including a biomass pretreatment process; and a process for producing a methane biogas with a reduced level of carbon dioxide and hydrogen sulfide, via an algae cultivation process with a view to purifying the carbon dioxide and hydrogen sulfide contained in the biogas; wherein, when the algae to be cultivated is microalgae, biodiesel is produced by subjecting the harvested microalgae to a biodiesel manufacturing process while recycling the glycerol and the saccharide-containing waste produced as byproducts to the biosaccharification/alcohol fermentation process, and when the algae to be cultivated is

Abstract: The present invention is about preparing gelatin nanoparticles having a size of about 200 nm are supported or not supported with a hardly-water soluble drug without a homogenizer by constructing O/W/O or W/O systems, thereby relatively prolonging the circulation time within the human body as compared to a water-repellent particle because it is free from the immune system, and enhancing EPR (Enhanced permeability and retention) effects. In this case, the hardly-water soluble drug includes hardly soluble anticancer agents such as paclitaxel, coenzyme Q10, ursodexoychlic acid, ilaprazole or imatinib mesylate. Furthermore, the O/W/O or W/O systems are nonpolar phase/polar phase/nonvolatile nonpolar phase and polar phase/nonvolatile nonpolar phase systems, respectively. More specifically, the O/W/O or W/O systems presents a hardly soluble drug/gelatin nanoparticle/fatty acid and gelatin nanoparticle/fatty acid systems, respectively.